Experts review the scientific rationale for combining BRAF, MEK and EGFR inhibition in BRAF-mutated mCRC; a strategy tested in such settings as the ANCHOR and BEACON trials.
Newsletter
Stay up to date on the most recent and practice-changing oncology data